Market Trends of Psoriatic Arthritis Therapeutics Industry
The Immunosuppressants Segment is Expected to Hold a Significant Market Share
Immunosuppressants are expected to experience the fastest growth in the psoriasis drugs market during the forecast period. This is due to several factors, including their improved safety and efficacy compared to other drug classes, which have led to increased patient adoption.
Major approved antibodies targeting interleukins, such as Taltz (ixekizumab), Cosentyx (secukinumab), Siliq (brodalumab), Tremfya (guselkumab), Ilumya (tildrakizumab), and SKYRIZI (risankizumab), aid in the adoption of immunosuppressants among the patient population.
In September 2022, the US Food and Drug Administration (USFDA) approved Deucravacitinib, an oral selective tyrosine kinase 2 (TYK2) inhibitor, for treating adults with moderate to severe plaque psoriasis eligible for systemic therapy or phototherapy. Furthermore, in August 2022, the US FDA greenlit ustekinumab (STELARA), which was the first and only biologic medication for treating active psoriatic arthritis (PsA) in pediatric patients aged 6 years and above. These regulatory nods are bolstering the segment's growth.
According to data from PubMed published in December 2022, immunosuppressants used for the treatment of psoriatic arthritis were tolerable and safe, increasing the demand for these drugs in the market. Therefore, the safety and tolerability of immunosuppressants boost their adoption in the highly affected elderly population, thereby fostering segment expansion.
Therefore, the significance of immunosuppressants and new launches are expected to contribute to market growth during the forecast period.
North America is Expected to Hold a Major Market Share During the Forecast Period
North America is projected to hold a major share of the psoriatic arthritis treatment market due to several factors. One of the primary reasons for this is the region's growing prevalence of psoriatic arthritis and obesity, which has increased awareness of the condition.
Furthermore, the advent of advanced therapies for psoriatic arthritis has led to an increase in adoption. For instance, according to the study published in the Journal of Rheumatology in May 2024, advanced therapies enhanced patient outcomes in psoriatic arthritis (PsA) in the Canadian population. Therefore, enhanced patient outcomes are anticipated to bolster market demand, driving market growth in the region.
Developed countries such as the United States and Canada have established healthcare systems that have a rapid adoption rate for new drugs, therapies, and technologies. As a result, expenditures on psoriatic arthritis therapeutics are expected to rise as the disease becomes more prevalent in the future.
Furthermore, rising initiatives from the key market players, such as partnerships for commercializing psoriatic therapies in the United States, are anticipated to propel market growth due to increased accessibility. For instance, in February 2024, Biocon Biologics, a subsidiary of Biocon, entered a significant settlement and licensing agreement with Janssen Biotech Inc. This agreement facilitates the commercialization of Bmab 1200, a proposed biosimilar to Stelara, in the United States for treating psoriasis, Crohn’s disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis.
Therefore, owing to the benefits associated with advanced psoriatic treatments and key initiatives by the market players, the North American market is expected to record rapid growth over the forecast period.
